Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.

Su B, Dispinseri S, Iannone V, Zhang T, Wu H, Carapito R, Bahram S, Scarlatti G, Moog C.

Front Immunol. 2019 Dec 18;10:2968. doi: 10.3389/fimmu.2019.02968. eCollection 2019. Review.

2.

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.

Sliepen K, Han BW, Bontjer I, Mooij P, Garces F, Behrens AJ, Rantalainen K, Kumar S, Sarkar A, Brouwer PJM, Hua Y, Tolazzi M, Schermer E, Torres JL, Ozorowski G, van der Woude P, de la Peña AT, van Breemen MJ, Camacho-Sánchez JM, Burger JA, Medina-Ramírez M, González N, Alcami J, LaBranche C, Scarlatti G, van Gils MJ, Crispin M, Montefiori DC, Ward AB, Koopman G, Moore JP, Shattock RJ, Bogers WM, Wilson IA, Sanders RW.

Nat Commun. 2019 May 29;10(1):2355. doi: 10.1038/s41467-019-10262-5.

3.

Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1.

Lewis GK, Ackerman ME, Scarlatti G, Moog C, Robert-Guroff M, Kent SJ, Overbaugh J, Reeves RK, Ferrari G, Thyagarajan B.

Front Immunol. 2019 May 10;10:1025. doi: 10.3389/fimmu.2019.01025. eCollection 2019. Review.

4.

Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae.

Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Lefebvre C, Hocini H, Benjelloun F, Cannou C, Nozza S, Dereuddre-Bosquet N, Levy Y, Barré-Sinoussi F, Scarlatti G, Le Grand R, Menu E.

Front Immunol. 2019 Mar 12;10:430. doi: 10.3389/fimmu.2019.00430. eCollection 2019.

5.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

6.

Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers.

Aldon Y, McKay PF, Allen J, Ozorowski G, Felfödiné Lévai R, Tolazzi M, Rogers P, He L, de Val N, Fábián K, Scarlatti G, Zhu J, Ward AB, Crispin M, Shattock RJ.

Cell Rep. 2018 Sep 18;24(12):3324-3338.e5. doi: 10.1016/j.celrep.2018.08.051.

7.

Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses.

Chissumba RM, Luciano A, Namalango E, Bauer A, Bhatt N, Wahren B, Nilsson C, Geldmacher C, Scarlatti G, Jani I, Kestens L; TaMoVac II group.

Immunobiology. 2018 Dec;223(12):792-801. doi: 10.1016/j.imbio.2018.08.006. Epub 2018 Aug 12.

PMID:
30121146
8.

Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.

Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ.

Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075.

9.

Editorial: HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies.

Chiodi F, Scarlatti G.

Front Immunol. 2018 Feb 20;9:297. doi: 10.3389/fimmu.2018.00297. eCollection 2018. No abstract available.

10.

Recent progress in immune-based interventions to prevent HIV-1 transmission to children.

Voronin Y, Jani I, Graham BS, Cunningham CK, Mofenson LM, Musoke PM, Permar SR, Scarlatti G.

J Int AIDS Soc. 2017 Dec;20(4). doi: 10.1002/jia2.25038.

11.

Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicity-Mediating Antibodies in a Rabbit Vaccination Model.

Karlsson I, Borggren M, Jensen SS, Heyndrickx L, Stewart-Jones G, Scarlatti G, Fomsgaard A.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):206-217. doi: 10.1089/AID.2017.0140. Epub 2017 Nov 17.

PMID:
28982260
12.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Viegas EO, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O, Stout R, Scarlatti G, Ferrari G, Earl PL, Wahren B, Andersson S, Robb ML, Osman N, Biberfeld G, Jani I, Sandström E.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):193-205. doi: 10.1089/AID.2017.0121. Epub 2017 Nov 27.

13.

Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry.

Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Hocini H, Benjelloun F, Cannou C, Dereuddre-Bosquet N, Levy Y, Barré-Sinoussi F, Scarlatti G, Le Grand R, Menu E.

J Immunol. 2017 Sep 1;199(5):1923-1932. doi: 10.4049/jimmunol.1700320. Epub 2017 Jul 31.

14.

HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights.

Shacklett BL, Derdeyn CA, Folayan MO, Landovitz RJ, Anthony C, Behrens AJ, Hope TJ, Landais E, Leal L, Marrazzo JM, Morris L, Mugo N, Ngure K, Noseda V, Ranasinghe S, Tully DC, Voronin Y, Warren M, Wibmer CK, Xie IY, Scarlatti G, Thyagarajan B.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):749-759. doi: 10.1089/AID.2017.0125. Epub 2017 Jul 26.

15.

Occupational HIV Infection in a Research Laboratory With Unknown Mode of Transmission: A Case Report.

Soria A, Alteri C, Scarlatti G, Bertoli A, Tolazzi M, Balestra E, Bellocchi MC, Continenza F, Carioti L, Biasin M, Trabattoni D, Bandera A, Ceccherini-Silberstein F, Perno CF, Gori A.

Clin Infect Dis. 2017 Mar 15;64(6):810-813. doi: 10.1093/cid/ciw851.

16.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, Tecleab T, Liakina V, Scarlatti G, Robb ML, Earl PL, Moss B, Wahren B, Mhalu F, Ferrari G, Sandstrom E, Biberfeld G.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):880-888. doi: 10.1089/AID.2016.0251. Epub 2017 Jan 27.

17.

Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.

Le Grand R, Dereuddre-Bosquet N, Dispinseri S, Gosse L, Desjardins D, Shen X, Tolazzi M, Ochsenbauer C, Saidi H, Tomaras G, Prague M, Barnett SW, Thiebaut R, Cope A, Scarlatti G, Shattock RJ.

J Virol. 2016 May 12;90(11):5315-5328. doi: 10.1128/JVI.00230-16. Print 2016 Jun 1.

18.

Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets.

Pogliaghi M, Ripa M, Pensieroso S, Tolazzi M, Chiappetta S, Nozza S, Lazzarin A, Tambussi G, Scarlatti G.

PLoS One. 2015 Oct 16;10(10):e0140435. doi: 10.1371/journal.pone.0140435. eCollection 2015.

19.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

20.

Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.

Ripa M, Pogliaghi M, Chiappetta S, Galli L, Pensieroso S, Cavarelli M, Scarlatti G, De Biasi S, Cossarizza A, De Battista D, Malnati M, Lazzarin A, Nozza S, Tambussi G.

Clin Microbiol Infect. 2015 Sep;21(9):876.e1-4. doi: 10.1016/j.cmi.2015.05.007. Epub 2015 May 14.

21.

Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.

Moroni M, Ghezzi S, Baroli P, Heltai S, De Battista D, Pensieroso S, Cavarelli M, Dispinseri S, Vanni I, Pastori C, Zerbi P, Tosoni A, Vicenzi E, Nebuloni M, Wong K, Zhao H, McHugh S, Poli G, Lopalco L, Scarlatti G, Biassoni R, Mullins JI, Malnati MS, Alfano M.

J Transl Med. 2014 Dec 5;12:335. doi: 10.1186/s12967-014-0335-6.

22.

Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.

Cavarelli M, Mainetti L, Pignataro AR, Bigoloni A, Tolazzi M, Galli A, Nozza S, Castagna A, Sampaolo M, Boeri E, Scarlatti G.

AIDS Res Hum Retroviruses. 2014 Dec;30(12):1243-50. doi: 10.1089/aid.2014.0124.

23.

Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition.

Sheik-Khalil E, Bray MA, Özkaya Şahin G, Scarlatti G, Jansson M, Carpenter AE, Fenyö EM.

BMC Infect Dis. 2014 Aug 30;14:472. doi: 10.1186/1471-2334-14-472.

24.

Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.

Uchtenhagen H, Schiffner T, Bowles E, Heyndrickx L, LaBranche C, Applequist SE, Jansson M, De Silva T, Back JW, Achour A, Scarlatti G, Fomsgaard A, Montefiori D, Stewart-Jones G, Spetz AL.

J Immunol. 2014 Jun 15;192(12):5802-12. doi: 10.4049/jimmunol.1301898. Epub 2014 May 14.

25.

HIV-1 infection: the role of the gastrointestinal tract.

Cavarelli M, Scarlatti G.

Am J Reprod Immunol. 2014 Jun;71(6):537-42. doi: 10.1111/aji.12245. Epub 2014 Apr 2. Review.

PMID:
24689691
26.

Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC).

Palma P, Romiti ML, Montesano C, Santilli V, Mora N, Aquilani A, Dispinseri S, Tchidjou HK, Montano M, Eriksson LE, Baldassari S, Bernardi S, Scarlatti G, Wahren B, Rossi P.

PLoS One. 2013 Nov 28;8(11):e79957. doi: 10.1371/journal.pone.0079957. eCollection 2013.

27.

Determination of HIV-1 co-receptor usage.

Cavarelli M, Scarlatti G.

Methods Mol Biol. 2014;1087:197-206. doi: 10.1007/978-1-62703-670-2_16.

PMID:
24158824
28.

HIV-1 isolation from infected peripheral blood mononuclear cells.

Dispinseri S, Saba E, Vicenzi E, Kootstra NA, Schuitemaker H, Scarlatti G.

Methods Mol Biol. 2014;1087:187-96. doi: 10.1007/978-1-62703-670-2_15.

PMID:
24158823
29.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

30.

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.

Visciano ML, Tagliamonte M, Stewart-Jones G, Heyndrickx L, Vanham G, Jansson M, Fomsgaard A, Grevstad B, Ramaswamy M, Buonaguro FM, Tornesello ML, Biswas P, Scarlatti G, Buonaguro L; NGIN Consortium.

J Transl Med. 2013 Jul 8;11:165. doi: 10.1186/1479-5876-11-165.

31.

A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion.

Petitdemange C, Achour A, Dispinseri S, Malet I, Sennepin A, Ho Tsong Fang R, Crouzet J, Marcelin AG, Calvez V, Scarlatti G, Debré P, Vieillard V.

Clin Infect Dis. 2013 Sep;57(5):745-55. doi: 10.1093/cid/cit335. Epub 2013 May 21.

PMID:
23696512
32.

R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the CCR5.

Cavarelli M, Foglieni C, Rescigno M, Scarlatti G.

EMBO Mol Med. 2013 May;5(5):776-94. doi: 10.1002/emmm.201202232. Epub 2013 Apr 22.

33.

B-cell subset alterations and correlated factors in HIV-1 infection.

Pensieroso S, Galli L, Nozza S, Ruffin N, Castagna A, Tambussi G, Hejdeman B, Misciagna D, Riva A, Malnati M, Chiodi F, Scarlatti G.

AIDS. 2013 May 15;27(8):1209-17. doi: 10.1097/QAD.0b013e32835edc47.

PMID:
23343911
34.

Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles EJ, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Grand RL, Fomsgaard A.

Vaccines (Basel). 2013 Jul 19;1(3):305-27. doi: 10.3390/vaccines1030305.

35.

HIV-derived vectors for gene therapy targeting dendritic cells.

Rossetti M, Cavarelli M, Gregori S, Scarlatti G.

Adv Exp Med Biol. 2013;762:239-61. doi: 10.1007/978-1-4614-4433-6_9. Review.

PMID:
22975878
36.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.

Ruffin N, Borggren M, Euler Z, Fiorino F, Grupping K, Hallengärd D, Javed A, Mendonca K, Pollard C, Reinhart D, Saba E, Sheik-Khalil E, Sköld A, Ziglio S, Scarlatti G, Gotch F, Wahren B, Shattock RJ.

J Transl Med. 2012 Jul 11;10:144. doi: 10.1186/1479-5876-10-144.

37.

International network for comparison of HIV neutralization assays: the NeutNet report II.

Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G.

PLoS One. 2012;7(5):e36438. doi: 10.1371/journal.pone.0036438. Epub 2012 May 9.

38.

Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies.

Cavarelli M, Scarlatti G.

J Intern Med. 2011 Dec;270(6):561-79. doi: 10.1111/j.1365-2796.2011.02458.x. Epub 2011 Oct 27.

39.

A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2.

Gatto F, Cassina G, Broccolo F, Morreale G, Lanino E, Di Marco E, Vardas E, Bernasconi D, Buttò S, Principi N, Esposito S, Scarlatti G, Lusso P, Malnati MS.

J Virol Methods. 2011 Dec;178(1-2):98-105. doi: 10.1016/j.jviromet.2011.08.022. Epub 2011 Aug 27.

PMID:
21903135
40.

Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.

Burastero SE, Frigerio B, Lopalco L, Sironi F, Breda D, Longhi R, Scarlatti G, Canevari S, Figini M, Lusso P.

PLoS One. 2011;6(7):e22081. doi: 10.1371/journal.pone.0022081. Epub 2011 Jul 19.

41.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

Brinckmann S, da Costa K, van Gils MJ, Hallengärd D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, Reudelsterz M, Ruffin N, Seifried J, Schäfer K, Sheik-Khalil E, Sköld A, Uchtenhagen H, Vabret N, Ziglio S, Scarlatti G, Shattock R, Wahren B, Gotch F.

J Transl Med. 2011 Apr 12;9:40. doi: 10.1186/1479-5876-9-40.

42.

HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infection.

Cavarelli M, Scarlatti G.

J Transl Med. 2011 Jan 27;9 Suppl 1:S10. doi: 10.1186/1479-5876-9-S1-S10. Review.

43.

Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Sabin C, Corti D, Buzon V, Seaman MS, Lutje Hulsik D, Hinz A, Vanzetta F, Agatic G, Silacci C, Mainetti L, Scarlatti G, Sallusto F, Weiss R, Lanzavecchia A, Weissenhorn W.

PLoS Pathog. 2010 Nov 18;6(11):e1001195. doi: 10.1371/journal.ppat.1001195.

44.

Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children.

Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyo EM, Scarlatti G.

AIDS. 2010 Oct 23;24(16):2527-33. doi: 10.1097/QAD.0b013e32833d7d8c.

PMID:
20683317
45.

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.

Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, Dieltjens T, Dispinseri S, Grupping K, Hallengärd D, Hornig J, Klein K, Mainetti L, Palma P, Reudelsterz M, Seifried J, Selhorst P, Sköld A, Uchtenhagen H, van Gils MJ, Weber C, Shattock R, Scarlatti G.

J Transl Med. 2010 Jul 26;8:72. doi: 10.1186/1479-5876-8-72. Erratum in: J Transl Med. 2010;8(1):82. Uchtenhagen, Hannes [added].

46.

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

Ross AL, Bråve A, Scarlatti G, Manrique A, Buonaguro L.

Lancet Infect Dis. 2010 May;10(5):305-16. doi: 10.1016/S1473-3099(10)70069-4.

PMID:
20417413
47.

Impact of host cell variation on the neutralization of HIV-1 in vitro.

Polonis VR, Schuitemaker H, Bunnik EM, Brown BK, Scarlatti G.

Curr Opin HIV AIDS. 2009 Sep;4(5):400-7. doi: 10.1097/COH.0b013e32832edc50. Review.

PMID:
20048704
48.

Phenotype variation in human immunodeficiency virus type 1 transmission and disease progression.

Cavarelli M, Scarlatti G.

Dis Markers. 2009;27(3):121-36. doi: 10.3233/DMA-2009-0656. Review.

49.

HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes.

Baroni M, Matucci A, Scarlatti G, Soprana E, Rossolillo P, Lopalco L, Zipeto D, Siccardi AG, De Santis C.

J Gen Virol. 2010 Jan;91(Pt 1):235-41. doi: 10.1099/vir.0.015230-0. Epub 2009 Sep 23.

PMID:
19776241
50.

International network for comparison of HIV neutralization assays: the NeutNet report.

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G.

PLoS One. 2009;4(2):e4505. doi: 10.1371/journal.pone.0004505. Epub 2009 Feb 20.

Supplemental Content

Loading ...
Support Center